The Food and Drug Administration (FDA) considers aging to be a natural process. This makes it difficult to get FDA approval for drugs that seek to slow or reverse the biological process of aging.
In contrast, anti-aging drugs must target a disease that often results from the aging process in order for the agency to demonstrate efficacy and grant approval.
However, it exists an increasing effort among scientists to convince the FDA that aging itself should be classified as a disease for drug development.
This could be an important milestone not only for the industry, but also for society.
If the FDA is affected, the resulting regulatory change could mean the approval of drugs or treatments that slow or reverse the aging process in general, before a patient develops a disease.
Researchers who view aging as a medical condition are not just referring to the inevitable passage of time.
Instead, they see aging as a process of deterioration in our structure and function at the cellular level, characterized by genomic instability and damage to our DNA.
The World Health Organization (WHO) supports this view and describes the aging process as “… the impact of the accumulation of a wide variety of molecular and cellular damage over time”.
Finally, let us mention that the "researchers" mentioned above need money for their research. Who funds this kind of research is important, as it can explain a lot of the unexplained.
For example, if a pharmaceutical company funds research, you can be sure that it is not just for science.